Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.60 |
| ▸ | CTSL | P07711 | 4/20 | 0.58 |
| ▸ | CTSB | P07858 | 4/20 | 0.58 |
| ▸ | CTSS | P25774 | 2/20 | 0.58 |
| ▸ | CTSK | P43235 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7293242 | 1.00 | TACR1 (0.60) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL8617156 | 0.88 | TACR1 (0.61) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL3044116 | 0.86 | TACR1 (0.60) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL4980616 | 0.86 | TACR1 (0.62) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL7490981 | 0.86 | TACR1 (0.62) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL6439753 | 0.86 | TACR1 (0.62) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL8699187 | 0.86 | TACR1 (0.65) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL7287480 | 0.86 | CTSK (0.66) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL7287486 | 0.86 | CTSK (0.66) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL4965672 | 0.86 | CTSL (0.47) | TACR1CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180271886-A1 | TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-9925202-B2 | Treatment of lymphangioleiomyomatosis | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160129030-A1 | TREATMENT OF MTOR HYPERACTIVE RELATED DISEASES AND DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160022706-A1 | TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2409149-B1 | METHODS OF SCREENING USING AMPHIBIANS | BRÄNDLI ANDRÉ W (CH) | 2015-11-11 | — | — | EP | disclosed |
| WO-2014201111-A1 | TREATMENT OF MTOR HYPERACTIVE RELATED DISEASES AND DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014137978-A1 | TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-1994025581-A1 | MODIFIED RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR | SOUTHERN SYDNEY AREA HEALTH SERVICE (AU) | 1994-11-10 | — | — | WO | disclosed |
| EP-0263903-A1 | Method for preparing specific inhibitors of virus-specified proteases | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-04-20 | — | — | EP | disclosed |
| EP-0263214-A1 | Tetrapeptide methyl ketone inhibitors of viral proteases | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-04-13 | — | — | EP | disclosed |
| EP-0263202-A1 | Inhibition of viral protease activity by peptide halomethyl ketones | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-04-13 | — | — | EP | disclosed |
| US-4652552-A | ENZYME INHIBITORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-03-24 | — | — | US | disclosed |
| US-4644055-A | HALOMETHYL KETONE OR METHYL KETONE COVALENTLY LINKED TO PEPTIDE SEQUENCE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-02-17 | — | — | US | disclosed |
| US-4636492-A | ENZYME INHIBITORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129030-A1 | TREATMENT OF MTOR HYPERACTIVE RELATED DISEASES AND DISORDERS | MTOR, RICTOR, LAMTOR3 | TACR1 200/4885CTSL 105/4885CTSB 285/4885 |
| US-20160022706-A1 | TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS | PTGER1, PTGS1, PTGES | TACR1 4262/4885CTSL 1566/4885CTSB 641/4885 |
| US-20180271886-A1 | TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS | PTGS1, PTGS2, PTGES2 | TACR1 3806/4885CTSL 1304/4885CTSB 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.